Group 1 - The brain-computer interface sector is experiencing a significant rise, with several companies showing strong performance [1] - Innovative Medical has reached its daily limit increase, indicating strong investor interest and confidence [1] - Qi Sheng Technology previously hit its limit up, reflecting positive market sentiment towards the company [1] Group 2 - Companies such as Xiangyu Medical, Mcland, and Beiyikang have all seen their stock prices increase by over 10%, showcasing a broader trend of growth in the sector [1] - Other companies including Aipeng Medical, Chengyitong, Sanbo Brain Science, Weisi Medical, and Lihua Science and Technology are also experiencing upward movement in their stock prices [1]

人民财讯8月12日电，诚益通（300430）8月12日在互动平台表示，公司已确立"侵入式与非侵入式"双轨 并行的战略布局，在非侵入式严肃医疗赛道，公司目前主要将现有康复设备与脑机接口进行结合，升级 现有产品功能，并积极推进相关商业化落地；除医疗领域外，公司也在积极探索"非医疗"场景的应用， 包括教育、养老、健康等多个领域，其中，在教育领域，公司已推出面向专注力检测与训练的脑机接口 生物反馈系统。在侵入式领域，公司脑机接口技术研究验证中心与动物实验中心正在建设中，作为公司 在脑机接口领域的重要战略布局，两大中心将构建"基础研究—技术验证—成果转化"的完整创新链条。 ...

诚益通（300430.SZ）8月12日在投资者互动平台表示，公司已确立"侵入式与非侵入式"双轨并行的战略 布局，在非侵入式严肃医疗赛道，公司目前主要将现有康复设备与脑机接口进行结合，升级现有产品功 能，并积极推进相关商业化落地；除医疗领域外，公司也在积极探索"非医疗"场景的应用，包括教育、 养老、健康等多个领域，其中，在教育领域，公司已推出面向专注力检测与训练的脑机接口生物反馈系 统。在侵入式领域，公司脑机接口技术研究验证中心与动物实验中心正在建设中，作为公司在脑机接口 领域的重要战略布局，两大中心将构建"基础研究-技术验证-成果转化"的完整创新链条。 每经AI快讯，有投资者在投资者互动平台提问：请问公司下属脑连科技的bci脑控机器人相关开发进度 如何？有哪些储备技术和产品？ （文章来源：每日经济新闻） ...

Group 1 - The core stock price of Chengyitong closed at 21.39 yuan on August 11, with a slight increase of 0.04 yuan from the previous trading day [1] - The trading volume for the day was 305,876 hands, with a total transaction amount of 657 million yuan, and the stock experienced a fluctuation of 5.71% [1] - Chengyitong operates in the general equipment manufacturing industry, focusing on smart manufacturing and biomedical sectors, with products including automation control systems and medical rehabilitation equipment [1] Group 2 - On the morning of August 11, Chengyitong's stock experienced a rapid decline, dropping over 2% within five minutes, reaching a low of 20.81 yuan before recovering slightly by the end of the day [1] - The net outflow of main funds on that day was 39.62 million yuan, with a cumulative net outflow of 98.78 million yuan over the past five trading days [1]

Group 1 - The brain-computer interface (BCI) concept stocks have been active, with multiple stocks rising significantly, and several exceeding 100% increase in price year-to-date [1][3][4] - A recent policy document issued by seven government departments aims to accelerate the BCI industry's development, proposing 17 specific measures to enhance hardware and software capabilities, application of technological achievements, and support for innovation [2][4] - The document outlines a roadmap for BCI development, with milestones set for 2025 and 2027, including the establishment of a comprehensive support system and the cultivation of leading enterprises [5][6] Group 2 - The policy encourages various application scenarios, including industrial manufacturing, healthcare, and consumer applications, aiming to break down departmental barriers and enhance collaboration across the industry [7][8] - The BCI industry is transitioning from research to commercialization, with significant advancements in non-invasive technologies and ongoing efforts to develop core components domestically [8][9] - The medical sector is identified as the fastest-growing area for BCI commercialization, with a projected global market size of $40 billion by 2030, driven by the treatment of central nervous system diseases [9][10] Group 3 - Recent developments include the establishment of pricing for BCI medical services, with specific costs outlined for invasive and non-invasive procedures, providing a foundation for clinical application [12][13] - Several listed companies are actively engaging in the BCI sector, with ongoing research and product development in invasive and semi-invasive BCI applications [13][15] - Companies are also preparing to establish funds and partnerships to support innovation and investment in the BCI field, indicating a strong interest in the sector's growth [14][15]

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant growth in the A-share market, with the BCI index reaching a historical high, indicating a promising future for the industry [2][3]. Industry Overview - The BCI technology is seen as a new frontier, with applications in medical fields such as disease warning, diagnosis, treatment, and functional enhancement, as well as in non-medical sectors like consumer and industrial applications [5][6]. - The global market for BCI medical applications is projected to reach $40 billion by 2030 and $145 billion by 2040, highlighting the substantial growth potential in this sector [5]. Company Developments - Several companies, including Sainuo Medical, Guangdian Co., and Shangrong Medical, have seen their stock prices surge, with multiple stocks hitting the daily limit up [3]. - Companies like Lide Man and Botuo Bio have reported significant gains, with Lide Man increasing over 11% and Botuo Bio rising by 10% [3]. - Sanbo Brain Science has completed an interventional BCI trial, showcasing China's innovation capabilities in this field and marking a significant step in treating movement disorders [3]. Strategic Initiatives - Chengyitong has established a dual-track strategy focusing on both invasive and non-invasive BCI technologies, aiming to integrate existing rehabilitation devices with BCI [4]. - Yanshan Technology's subsidiary has developed a brain-computer interface system that has demonstrated excellent performance in clinical trials, indicating advancements in the technology [5]. Policy Support - The Chinese government has been actively promoting the BCI industry through various policies, with multiple regions releasing action plans to accelerate development [6]. - The Ministry of Industry and Information Technology has outlined goals for the BCI sector over the next five years, aiming for breakthroughs in key technologies and the establishment of a robust industrial ecosystem by 2030 [6][7]. Market Challenges and Opportunities - The BCI industry faces challenges in making technology affordable for the general public, with current rehabilitation robots costing around 1 million yuan, which is still considered expensive [7][8]. - The integration of BCI technologies into medical insurance reimbursement lists is seen as a critical step for commercial viability and wider adoption [8].

Core Viewpoint - The brain-computer interface (BCI) industry is expected to experience significant growth, with 2023 being a pivotal year for its development and application across various sectors [2][8]. Group 1: Market Performance - The BCI concept stocks have seen a strong rally, with several companies like Sainuo Medical, Guangdian Co., and Shangrong Medical hitting their daily price limits [4]. - Notable stock performances include Lide Man and Botuo Bio, which rose over 11%, and Meilan De, which increased by 10% [4]. Group 2: Technological Advancements - BCI technology connects the brain with external devices for information exchange, showing promise in medical fields such as disease diagnosis and treatment [6]. - Significant advancements have been made in BCI technology, particularly in biomedical applications, neuro-rehabilitation, and intelligent robotics [6]. Group 3: Industry Outlook - According to McKinsey, the global market for BCI medical applications is projected to reach $40 billion by 2030 and $145 billion by 2040 [7]. - The Chinese BCI industry, although starting late, is rapidly developing, with multiple policies introduced since 2025 to support its growth [9][10]. Group 4: Policy Support - Recent government initiatives aim to accelerate the commercialization of BCI technology, with specific action plans released by cities like Beijing and Shanghai [9][10]. - The Ministry of Industry and Information Technology and other departments have set ambitious goals for the BCI industry over the next five years, focusing on technological breakthroughs and establishing a robust industrial ecosystem [10]. Group 5: Application Areas - The BCI industry has two primary application areas: serious medical applications, such as rehabilitation for stroke and spinal injury patients, and consumer applications addressing issues like sleep disorders [11]. - A significant challenge for the industry is to reduce costs, making BCI technologies more accessible to the general public [11][12].

本报记者 许林艳 8月8日，脑机接口概念股进一步上涨。截至午间收盘，际华集团（601718）涨停，麦澜德涨停超10%， 三博脑科（301293）、乐普医疗（300003）涨超8%，爱朋医疗（300753）、诚益通（300430）等纷纷 跟涨。 福州公孙策公关咨询有限公司合伙人詹军豪表示，目前我国脑机接口技术已取得显著进展，非侵入式技 术在医疗康复等领域实现初步应用，侵入式技术也进入了临床试验阶段。 根据中国电子信息产业发展研究院数据，2024年中国脑机接口市场规模为32亿元，同比增长18.8%；预 计到2027年将达到55.8亿元。 多地均在积极推进脑机接口产业发展。今年年初，北京印发《加快北京市脑机接口创新发展行动方案 （2025-2030年）》，其中提出，到2030年打造1-2个脑机接口产业发展集聚示范区，实现脑机接口创新 产品在医疗、康养、工业、教育等领域的规模化商用。 同期，上海印发《上海市脑机接口未来产业培育行动方案（2025-2030年）》，其中提出2030年前，实 现高质量控脑，脑机接口产品全面实现临床应用，打造全球脑机接口产品创新高地，产业链核心环节实 现自主可控。 政策利好不断，脑机接口产业 ...

Group 1 - The brain-computer interface concept stocks have seen a significant increase, with companies like Innovation Medical and Jihua Group reaching their daily limit up [1] - Beikang has risen over 20%, while Sanbo Neuroscience, Aipeng Medical, and Chengyitong have all increased by more than 10% [1]

（文章来源：证券日报） 证券日报网讯诚益通8月4日在互动平台回答投资者提问时表示，公司脑机产品未来取得医疗器械注册证 并销售到医院之后就可以在医院使用了。 ...